Last reviewed · How we verify
atezolizumab + avastin + platinum-based chemotherapy
This combination uses an immune checkpoint inhibitor to block PD-L1, an anti-angiogenic monoclonal antibody to inhibit VEGF-mediated tumor blood vessel formation, and platinum-based chemotherapy to directly damage tumor DNA.
This combination uses an immune checkpoint inhibitor to block PD-L1, an anti-angiogenic monoclonal antibody to inhibit VEGF-mediated tumor blood vessel formation, and platinum-based chemotherapy to directly damage tumor DNA. Used for Advanced or metastatic non-small cell lung cancer (NSCLC), Ovarian cancer (platinum-sensitive recurrent or advanced).
At a glance
| Generic name | atezolizumab + avastin + platinum-based chemotherapy |
|---|---|
| Also known as | Tecentriq |
| Sponsor | ARCAGY/ GINECO GROUP |
| Drug class | PD-L1 inhibitor + VEGF inhibitor + platinum-based chemotherapy combination |
| Target | PD-L1, VEGF, DNA (platinum adducts) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Atezolizumab (anti-PD-L1) restores anti-tumor immune responses by blocking the PD-L1/PD-1 axis. Bevacizumab (Avastin) inhibits VEGF signaling to reduce tumor angiogenesis and vascular permeability. Platinum chemotherapy (typically carboplatin or cisplatin) induces DNA crosslinks and apoptosis. The triple combination leverages immunotherapy, anti-angiogenesis, and cytotoxic chemotherapy to enhance tumor control.
Approved indications
- Advanced or metastatic non-small cell lung cancer (NSCLC)
- Ovarian cancer (platinum-sensitive recurrent or advanced)
Common side effects
- Fatigue
- Nausea and vomiting
- Neutropenia
- Anemia
- Thrombocytopenia
- Hypertension
- Proteinuria
- Immune-related adverse events (pneumonitis, hepatitis)
Key clinical trials
- A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (PHASE2)
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (PHASE2, PHASE3)
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer (PHASE1)
- A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101) (PHASE1)
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (PHASE2)
- A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours (PHASE1)
- Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: